New mRNA shot aims to tame stubborn gout
NCT ID NCT07587684
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new mRNA medicine called IN026 in 16 adults with refractory gout — gout that doesn't get better with standard treatments. The drug is given as an IV infusion and is designed to lower uric acid levels and shrink uric acid crystals (tophi). The main goal is to check safety, but researchers will also see if it helps control the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IN026 (an mRNA therapy given as an IV infusion)
What this could lead to
If it works, this could point toward a new treatment option for people with hard-to-control gout that doesn't respond to standard therapies.
What could go wrong
This is a very early, small Phase 1 trial with only 16 participants, so it's mainly checking safety. It may not lower uric acid effectively or could cause unexpected side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY GOUT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••